Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Adagene Starts Global Trial of CTLA-4 Inhibitor for Solid Tumor Cancers

publication date: Mar 16, 2021

Adagene, a Suzhou-San Francisco immunotherapy company, has begun dosing patients in a global Phase I trial of ADG126 in patients with advanced solid tumors. ADG126, Adagene’s lead SAFEbody™ product candidate, is a fully-human, antagonistic mAb targeting a novel epitope of CTLA-4. The company said its SAFEbody platform is designed to limit the safety issues of anti-CTLA-4 therapies by limiting on-target off-tumor toxicities in normal tissues. Adagene developed SAFEbody using its AI-powered platform. More details...

Stock Symbol: (NSDQ: ADAG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.